Related Experiment Video
Updated: Apr 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy
Ignacio Pérez Valero1, Alicia González-Baeza1, María Luisa Montes Ramírez1
1HIV Unit - Internal Medicine Service, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain.
Abstract:
Darunavir/ritonavir monotherapy is an experimental switching strategy for virologically suppressed patients without protease inhibitor resistance to avoid nucleos(t)ide-related toxicities. This therapy maintains virological suppression in most patients, but at slightly lower rates than standard therapy that includes two nucleos(t)ides. Patients experiencing virological failure are generally re-suppressed without emergence of resistance with the resumption of two nucleos(t)ides. Reports of cerebrospinal fluid viral escape has been observed in patients receiving protease inhibitor monotherapy, and concerns exist regarding the capacity of protease inhibitor monotherapy to control HIV infection in the brain and to prevent neurocognitive decline. In the current report we have pooled together available evidence regarding the capacity of darunavir/ritonavir monotherapy to control HIV replication in cerebrospinal fluid and to prevent neurocognitive decline.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Retrovirus Life Cycles
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Bioavailability: Influencing Factors
Pharmacokinetics: Drug–Drug Interactions

